Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome

Pediatric Nephrology

Volumn 20, Issue 11, 2005, Pages 1660-1663

  Nozu, Kandai ^a   Iijima, Kazumoto ^b   Fujisawa, Masato ^a   Nakagawa, Atsuko ^c   Yoshikawa, Norishige ^d   Matsuo, Masafumi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Epstein Barrvirus; Pediatric patient; Postrenal transplantation; Posttransplant lymphoproliferative disorder (PTLD); Recurrence of FSGS; Rituximab

Indexed keywords

ALBUMIN; CREATININE; CYCLOSPORIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MIZORIBINE; RITUXIMAB; TACROLIMUS;

ALBUMIN BLOOD LEVEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CREATININE URINE LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NEPHROTIC SYNDROME; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEINURIA; SCHOOL CHILD; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOMA, B-CELL; MALE; NEPHROTIC SYNDROME; RECURRENCE; REMISSION INDUCTION;

EID: 27644531469     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-005-2013-7     Document Type: Article

References (28)

1. Tejani A, Stablein DH (1992) Recurrence of focal segmental glomerulosclerosis post-transplantation: A special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 2 [Suppl 12]: S258-S263
2. Broyer M, Selwood N, Brunner F (1992) Recurrence of primary renal disease on kidney graft: A European pediatric experience. J Am Soc Nephrol 2 [Suppl 12]: S255-S257
3. Kershaw DB, Sedman AB, Kelsch RC, Bunchman TE (1994) Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients: successful treatment with oral cyclophosphamide. Clin Transplant 8:546-549 7865917
4. Srivastava RN, Kalia A, Travis LB, Diven SC, Gugliuzza KK, Rajaraman S (1994) Prompt remission of post-renal transplant nephrotic syndrome with high-dose cyclosporine. Pediatr Nephrol 8:94-95 10.1007/BF00868281
5. Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F (1992) Natural history and response to therapy. Am J Med 92:375-383 10.1016/ 0002-9343(92)90267-F
6. Zamora I, Simon J (1993) OKT3: A therapeutic alternative in recurrence of focal glomerulosclerosis in the transplanted kidney? Nephrol Dial Transplant 8:106 (letter)
7. Tejani A, Nicastri AD, Sen D, Chen CK, Phadke K, Adanmson O, Butt KM (1983) Long-term evaluation of children with nephrotic syndrome and focal segmental glomerular sclerosis. Nephron 35:225-231 6358923
8. Raafat RH, Kalia A, Travis LB, Diven SC (2004) High-dose oral cyclosporine therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 44:50-56 15211437
9. EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.5. Chronic graft dysfunction. Late recurrence of primary glomerulonephritides. Nephrol Dial Transplant 17 [Suppl 4]:16-18
10. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M (1991) A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40:453-460 1787645
11. Esnault VL, Besnier D, Testa A, Coville P, Simon P, Subra JF, Audrain AP (1999) Effect of protein A immunoabsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol 10:2014-2017 10477155
12. Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, Soulillou JP (1998) Antihuman immunoglobulin affinity immunoabsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9:1709-1715 9727380
13. Kakumitsu H, Higuchi M, Tanaka K, Shibuya T (2003) Nephrotic syndrome in a patient with intravascular lymphomatosis. Inter Med 42:98-101
14. Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE (2003) Combined T- and B-cell activation in childhood steroid-sensitive nephritic syndrome. Clin Nephrol 60:242-247 14579938
15. Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794-797 10.1007/s00467-004-1434-z
16. Pinkerton CR, Hann I, Weston CL, Mapp T, Wotherspoon A, Hobson R, Kelley DA, Vergani D, Hadzic D, Rees L, Burke M, Thomas JA (2002) Immunodeficiency-related lymphoproliferative disorders: Prospective data from the United Kingdom Children's Cancer Study Group. Br J Hematol 118:456-461 10.1046/j.1365-2141.2002.03681.x
17. Cook RC, Connor JM, Gascoyne RD, Fradet G, Levy RD (1999) Treatment of posttransplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 354:1698-1699 10.1016/ S0140-6736(99)02058-9
18. Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB (2000) Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation. Transplantation 69:430-432 10.1097/ 00007890-200002150-00021
19. Milpied N, Vasseurr B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V (2000) Humanized anti-CD20 monoclonal antibody (rituximab) in the post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 11: S113-116 10.1023/A:1008372814223
20. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, Rohrlich P, Peuchmaur M, Matthieu-Boue A, Fischer A, Vilmer E (2001) Chimeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Hematol 115:112-118 10.1046/j.1365-2141.2001.03041.x
21. McGhee W, Mazariegos V, Sindhi R, Abu-Elmagd K, Reyes J (2002) Rituximab in the treatment of pediatric small bowel transplant patients with posttransplant lymphoproliferative disorder unresponsive to standard treatment. Transplantation Proceedings 34:955-956 10.1016/ S0041-1345(02)02714-8
22. Serinet MO, Jacqemin E, Habes D, Debray D, Fabre M, Bernard O (2002) Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus associated B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 34:389-393 10.1097/ 00005176-200204000-00014
23. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincent F (1996) Circulating factor with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878-883 10.1056/ NEJM199604043341402
24. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS (1999) Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. Transplantation 68:1517-1525 10.1097/00007890-199911270-00015
25. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA (2001) Reduction in immunosuppression as initial therapy for post-transplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076-1088 10.1097/00007890-200104270-00012
26. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G. (2003) Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14:1851-1857 10.1097/ 01.ASN.0000071511.35221.B3
27. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum 52:501-513 10.1002/art.20858
28. Weiss SF, Nickolas TL, Radhakrishnan J, Appel GB (2004) Rituximab therapy of glomerular diseases. Abstract from American Society of Nephrology Renal Week 2004, 27 October-1 November 2004, St. Louis